This study first assessed the linkage of lnc-PKD2-2-3, miR-328, and GPAM with clinicopathological features in CCA patients and then evaluated their intercorrelation and effect on regulating CCA viability, mobility, and drug sensitivity. This evidence concerns the gene GPAM and cholangiocarcinoma.